.png)
Truscreen
Advancing Cervical Cancer Screening Technology
TruScreen is a portable medical device designed to detect pre-cancerous and cancerous cervical tissue in real time, helping expand access to cervical cancer screening worldwide.
Genesys partnered with TruScreen to modernise the device platform, transforming the first-generation system into a compact, wireless and user-friendly product while maintaining its diagnostic integrity and supporting global deployment.
.webp)
The Technology
The TruScreen device uses a combination of optical and electrical sensors to gather diagnostic data from multiple points on cervical tissue.
An AI-enabled algorithm analyses this data and compares it with known tissue signatures, enabling the device to provide an immediate result indicating whether the tissue is Normal or Abnormal.
This real-time diagnostic capability allows physicians to make immediate clinical decisions and plan appropriate patient care during the consultation.
The handheld device features:
• Integrated touchscreen interface
• Wireless connectivity for data export
• Portable, battery-powered operation
• Secure storage of diagnostic data
The Challenge
Every two minutes, a woman dies from cervical cancer.
Of the approximately 600,000 cases diagnosed globally each year, nearly half result in death, despite cervical cancer being largely preventable with effective screening.
In countries with well-established healthcare systems, routine screening programs such as Pap tests have significantly reduced mortality rates. However, these methods require specialised laboratories, trained personnel, and robust quality assurance processes.
In many low and middle income countries, these requirements create major barriers to effective screening. As a result, nearly 90% of cervical cancer deaths occur in regions where healthcare infrastructure is limited.
TruScreen developed a portable device capable of detecting pre-cancerous and cancerous cervical tissue in real time, enabling screening directly at the point of care without the need for laboratory analysis.
Genesys partnered with TruScreen to redesign and modernise the device platform, transforming the original system into a compact, wireless and user-friendly product while maintaining the diagnostic performance required for clinical use.
The Solution
Genesys Engineering Contribution
Genesys Electronics Design played a central role in transforming the original first-generation device into a modern, compact, and user-friendly system.
The original system was large and cumbersome. Genesys redesigned the platform into a sleek handheld unit with an integrated charging dock, improving both usability and portability.
One of the key engineering challenges was preserving the diagnostic integrity of the original device while transitioning to a new hardware architecture. Maintaining compatibility with existing diagnostic signatures was critical to minimise regulatory and commercial risks.
To support the new system architecture, Genesys:
• Redesigned the electronic circuitry to significantly reduce power consumption
• Integrated Wi-Fi connectivity for data transfer
• Optimised memory architecture to support increased storage capacity
• Reengineered the device to support wireless and battery-powered operation
The industrial design for the project was delivered by IDE Group.
Impact
Martin Dillon, former CEO of TruScreen, commented:
The TruScreen device provides clinicians with a powerful tool to perform immediate cervical cancer screening without the need for laboratory infrastructure, expanding access to early detection in regions where traditional screening programs are difficult to implement.
By enabling faster diagnosis and improving access to screening, the technology contributes to the global effort to reduce cervical cancer mortality worldwide.
From connected medical devices to diagnostic platforms, Genesys Electronics Design helps MedTech innovators bring their ideas to life.
